Novel Potential Anti-Psychotic Agents


Description

Researchers at the University of Alberta have designed a number of analogues of ßphenylethylidenehydrazine (PEH), two of which cause considerable increase of glycine in the brain in ex vivo studies in rats. Glycine is believed to excite the glutamatergic system, which is proposed to be hypofunctional in schizophrenia, and glycine agonists have been reported to be useful in treating negative and cognitive symptoms of schizophrenia. These observations suggest that our novel PEH analogues may be useful as potential antipsychotic drugs.

PEH is a known metabolite of the antidepressant / antipanic / neuroprotective drug phenelizine (PLZ). Research had suggested that PEH formation may contribute to some of the therapeutic effects of PLZ, such as neuroprotection.

 

Advantages

  • The PEH derivatives cause an indirect increase in glycine, which could potentially reduce the need of glycine agonists that have limited clinical use due to high dose requirement and side-effect profile.

 

Potential Markets

Pharmaceutical companies interested in antipsychotic agents for treating symptoms of schizophrenia.

Protection Status

Issued Patent

Product Number

2008069

Contact Information

Joanna Preston
Technology Management Group
TEC Edmonton – University of Alberta
Phone: 780-492-7120
​Email: joanna.preston@tecedmonton.com